The Renin-Aldosterone Axis in Postural Tachycardia Syndrome

Postural Orthostatic Tachycardia Syndrome (POTS) Clinical Trial

Official title:

The Renin-Aldosterone Axis in Postural Tachycardia Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00962949
• Other study ID #: 081398
• Secondary ID: PF334
• Status: Completed
• Phase: Phase 1
• Start date: April 2009
• Est. completion date: December 2012

Study information

• Verified date: November 2017
• Source: Vanderbilt University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the role of the renin-angiotensin-aldosterone in the pathophysiology of postural tachycardia syndrome, and to provide an insight about the disease process in this disorder.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: December 2012
• Est. primary completion date: December 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• Diagnosis of postural tachycardia syndrome by the Vanderbilt Autonomic Dysfunction Center criteria

• Age between 18-64 years

• Male or females are eligible

• Able and willing to provide informed consent

• Healthy control subjects with no major medical problem (including postural tachycardia syndrome), free of medications during the study

Exclusion Criteria:

• Overt cause of postural tachycardia e.g., dehydration

• Inability to give or withdraw informed consent

• Pregnancy

• Hypertension (BP > 140/90)

• Significant co-morbid condition

• Other factors which in the investigator`s opinion would prevent the subject from completing the protocol

Related Conditions & MeSH terms

• Postural Orthostatic Tachycardia Syndrome
• Postural Orthostatic Tachycardia Syndrome (POTS)
• Syndrome
• Tachycardia

Intervention

Drug:
• Angiotensin II
Angiotensin II infusion for 1 hour

Locations

Country	Name	City	State
United States	Vanderbilt University	Nashville	Tennessee

Sponsors (1)

Lead Sponsor	Collaborator
Vanderbilt University Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Arterial Blood Pressure Change		1 hour
Secondary	Plasma Renin Activity		1 hour
Secondary	Aldosterone Level		1 hour
Secondary	Cortisol Level		1 hour